← All candidates
Five insider buys in the last year — $25.3K in all.
16 filings on record.
PFSAProfusa, Inc.
NasdaqCM · Healthcare · $1.08M
$1.78
-2.73% today
Five insider buys in the last year — $25.3K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 5 buys● 5 sells◆ 17 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 3×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what PFSA ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.08M
Float
0.5M
86% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Hrt Financial LP
Bought $13.9K on Aug 3 — 14,556 sh @ $0.9580, held direct, 13% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
11 more transactions on Pro →Context
Coverage
Profusa vies for potential G3 Vision Labs acquisitionMedical Device Network · 08-03Profusa Signs Term Sheet for Diagnostics Acquisition and Announces Leadership ChangesInvestorsHub · 07-27This Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This YearStocktwits · 07-02Sector Update: Health Care Stocks Climb Late AfternoonMT Newswires · 09-11
The file stays open
16 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice